Nice efficacy data for Servier's vorasidenib in IDH1/2+ glioma in kind of a maintenance setting, with HR=0.39 for PFS in the Indigo study. But does this level of liver tox concern anyone? #Asco23
4
3
15
10K
1
Download Image
Also a 20 Aug 2024 Pdufa date for Servier's vorasidenib in IDH-mutant diffuse glioma (Indigo trial). I wonder if the probable cases of Hy's law will be a review issue, per #ASCO23 discussion.